Hyperthermic intraperitoneal chemotherapy (HIPEC)
Peritoneal cancer therapy remains a challenge. Currently, only the combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is currently the only potentially curative option with good results. Complete macroscopic cytoreduction is essential for good oncologic outcomes. This usually requires complex surgery with high mortality. Therefore, the multimodality procedure is only suitable for a few patients selected on many parameters. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a relatively new minimally invasive procedure, the value and scope of whose use have not yet been fully elucidated. Published work to date shows encouraging results. PIPAC is therefore a possible palliative therapy option for patients who are not suitable for CRS and HIPEC. This review summarizes the currently available data situation regarding CRS - HIPEC and PIPAC.
For more information, we at Medical Karaj are at your service.
Call us on the following numbers "Medical Karaj": 0879 977 401 or 0879 977 402.
Also keep an eye on our constantly updated Facebook content.
